Back to Search Start Over

Venous thromboembolic disease.

Authors :
Streiff MB
Bockenstedt PL
Cataland SR
Chesney C
Eby C
Fanikos J
Fogerty AE
Gao S
Goldhaber SZ
Hassoun H
Hendrie P
Holmstrom B
Kuderer N
Lee JT
Millenson MM
Neff AT
Ortel TL
Siddiqi T
Smith JL
Yee GC
Zakarija A
McMillian N
Naganuma M
Source :
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2013 Nov; Vol. 11 (11), pp. 1402-29.
Publication Year :
2013

Abstract

Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.

Details

Language :
English
ISSN :
1540-1413
Volume :
11
Issue :
11
Database :
MEDLINE
Journal :
Journal of the National Comprehensive Cancer Network : JNCCN
Publication Type :
Academic Journal
Accession number :
24225973
Full Text :
https://doi.org/10.6004/jnccn.2013.0163